ADJUVANT FORMULATIONS PLATFORM


AAHI pioneers the development and formulation of adjuvants – immunostimulants that boost the body’s natural immune response to disease. Our vaccine adjuvant technology is optimized to promote more potent, longer-lasting, and broadly protective immune responses specific to a target pathogen.

Our Adjuvant Formulations Platform has unparalleled breadth and diversity of application. AAHI adjuvant formulations enable and improve vaccines against infectious disease, cancer, allergies, and other pathogens and disorders.

GLA-SE-Vial-opt

AAHI’s robust adjuvant formulation portfolio allows vaccine developers to select an adjuvant formulation that maximizes the impact of their specific vaccine candidate.

ADJUVANT PORTFOLIO

  • TLR Ligands + Alum

  • NanoAlum

  • Aqueous Nanosuspension

  • TLR 4 Ligands

  • TLR7/8 Ligands

  • Saponin QS-21

  • Dual Agonist

TLR Ligands + Alum

What is it?

The adsorption of TLR ligands to Alum, which shifts immune response to Th1 quality.

Where does it come from?

AAHI developed a formulation approach to adsorb lipid-based TLR ligands to Alum.

Unique to AAHI

AAHI’s formulations of both TLR 4 ligands and TLR 7/8 ligands adsorbed to Alum are tested in humans.

Resources

3M-052-Alum Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

Find out how our adjuvant formulations are revolutionizing vaccines and immunotherapies worldwide.

STRONG AND DURABLE IMMUNE RESPONSE:


Adjuvants boost the innate immune response to disease, providing prolonged protection from disease and efficacy in at-risk populations with underdeveloped or waning immunity.

BREADTH OF PROTECTION:


AAHI adjuvant formulations are optimized to elicit a combination of T cells and antibodies for broader protection against viral variants. They can also be formulated with multivalent proteins that target multiple pathogens.

ACCESSIBILITY AND PANDEMIC RESPONSE:


Vaccine candidates that include AAHI adjuvant formulations can be made suitable for low resource areas by using spray and freeze-drying technologies that confer stability at room temperatures for up to three months, eliminating deep cold chain requirements and enabling alternative routes of delivery.

SERVICES

We provide custom solutions that can enhance vaccines with next generation features and functionality, creating unique products capable of addressing pressing global health needs.

Research Material Supply

Our formulations team can evaluate any AAHI adjuvant formulations with your vaccine antigen in preclinical studies.

Custom Formulations

Our formulations team can formulate your novel small molecule immunostimulator, or customize adjuvant formulations for optimal compatibility with your specific antigen.

Compatibility Studies

Our formulations team can perform a variety of assays testing the mixing compatibility of AAHI adjuvants mixed with your antigen of choice.

In Vitro Bioactivity

Our formulations team can determine if the adjuvant formulation or immunomodulatory compound of interest has innate immune stimulation properties on human cells.

OTHER SERVICES

Consulting

AAHI provides consulting services. We support development of preclinical studies that accelerate progress to clinic, clinical trial design and coordination, and applications for regulatory approval.

CONTACT US TO TEST AAHI ADJUVANT FORMULATIONS WITH YOUR VACCINE ANTIGEN TO DEVELOP A POTENT, DURABLE, AND BROADLY EFFECTIVE VACCINE.